Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.63 |
| ▸ | NAAA | Q02083 | 1/20 | 0.59 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | FAAH | O00519 | 2/20 | 0.53 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.53 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.52 |
| ▸ | RRM1 | P23921 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25885394 | 0.98 | CASP2 (0.67) | CASP2NAAAEPHX1MEN1KMT2A | |
| SCHEMBL25885398 | 0.98 | CASP2 (0.67) | CASP2NAAAEPHX1MEN1KMT2A | |
| SCHEMBL11246492 | 0.98 | CASP2 (0.67) | CASP2NAAAEPHX1MEN1KMT2A | |
| SCHEMBL11594186 | 0.98 | CASP2 (0.67) | CASP2NAAAEPHX1MEN1KMT2A | |
| SCHEMBL3172352 | 0.98 | CASP2 (0.67) | CASP2NAAAEPHX1MEN1KMT2A | |
| SCHEMBL1263917 | 0.98 | CASP2 (0.67) | CASP2NAAAEPHX1MEN1KMT2A | |
| SCHEMBL10708302 | 0.98 | CASP2 (0.67) | CASP2NAAAEPHX1MEN1KMT2A | |
| SCHEMBL29981433 | 0.98 | CASP2 (0.67) | CASP2NAAAEPHX1MEN1KMT2A | |
| SCHEMBL22776495 | 0.98 | CASP2 (0.67) | CASP2NAAAEPHX1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL23001108 | 0.96 | CASP2 (0.64) | CASP2NAAAEPHX1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100310477-A1 | Pharmaceutical compositions based on anticholingerics and additional active ingredients | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG. (DE) | 2010-12-09 | — | — | US | claimed |
| EP-1829539-A2 | A method for treating tension-type headache | HEADEXPLORER ApS (DK) | 2007-09-05 | — | — | EP | claimed |
| US-20050148562-A1 | Pharmaceutical compositions based on anticholinergics and additional active ingredients | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-07-07 | — | — | US | claimed |
| EP-0824530-B1 | ARYL GLYCINAMIDE DERIVATIVES, METHODS OF PRODUCING THESE SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-03-02 | — | — | EP | claimed |
| US-20040151770-A1 | Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-08-05 | — | — | US | claimed |
| US-20040097562-A1 | Method for treating tension-type headache | HEAD EXPLORER APS (DK) | 2004-05-20 | — | — | US | claimed |
| US-20040048886-A1 | Pharmaceutical compositions based on new anticholinergics and NK1 receptor antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-11 | — | — | US | claimed |
| US-6696042-B2 | INHALATION AEROSOL COMPRISING TIOTROPIUM SALT AND PROPELLANT GAS; RESPIRATORY SYSTEM DISORDERS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-02-24 | — | — | US | claimed |
| US-6649605-B2 | Administering amount of agent effective to interact with neuronal transmission connected with pain perception, so as to prevent or reduce central sensitization | HEAD EXPLORER A/S (DK) | 2003-11-18 | — | — | US | claimed |
| US-20030212075-A1 | PHARMACEUTICAL COMPOSITIONS BASED ON ANTICHOLINERGICS AND NK1-RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-11-13 | — | — | US | claimed |
| CN-1042728-C | Novel arylglycinamide derivatives and preparative processes therefor | KYOBAYASH PHARMACEUTICAL CO LT (JP) | 1999-03-31 | — | — | CN | claimed |
| CN-1212689-A | Novel aryl glycinamide derivatives, method of producing said derivatives and pharmaceutical compositions containing these compounds | BOEHRINGER INGELHEIM KG (DE) | 1999-03-31 | — | — | CN | claimed |
| US-5861509-A | NEUROKININ AND TACHYKININ ANTAGONISTS; RESPIRATORY SYSTEM DISORDERS, ANTIINFLAMMATORY AGENTS | BOEHRINGER INGELHEIM KG (DE) | 1999-01-19 | — | — | US | claimed |
| WO-1998019674-A2 | A METHOD FOR TREATING TENSION-TYPE HEADACHE | HEAD EXPLORER APS (DK) | 1998-05-14 | — | — | WO | claimed |
| CN-1180352-A | Aryl glycinamide derivatives, methods of producing these substances and pharmaceutical compositions containing such compounds | BOEHRINGER INGELHEIM KG (DE) | 1998-04-29 | — | — | CN | claimed |
| US-5710155-A | NEUROKIN ANTAGONISTS USEFUL IN TREATMENT OF RESPIRATORY, INFLAMMATORY AND GASTROINTESTINAL DISORDERS | BOEHRINGER INGELHEIM KG (DE) | 1998-01-20 | — | — | US | claimed |
| EP-0581167-B1 | Novel arylglycinamide derivatives and preparative processes therefor and their use for treatment of dysuria | KYORIN SEIYAKU KK (JP) | 1996-10-09 | — | — | EP | claimed |
| CN-1112109-A | Novel arylglycinamide derivatives and preparative processes therefor | KYOBAYASH PHARMACEUTICAL CO LT (JP) | 1995-11-22 | — | — | CN | claimed |
| US-5439919-A | Treatment of urinary incontinence | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1995-08-08 | — | — | US | claimed |
| EP-0581167-A1 | Novel arylglycinamide derivatives and preparative processes therefor and their use for treatment of dysuria | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1994-02-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148562-A1 | Pharmaceutical compositions based on anticholinergics and additional active ingredients | CHRM3, ADRA2C, PDE3A | CASP2 4352/4885NAAA 2318/4885EPHX1 787/4885 |
| US-20040151770-A1 | Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists | TACR2, CHRM3, TACR1 | CASP2 4578/4885NAAA 1349/4885EPHX1 1916/4885 |
| US-20100310477-A1 | Pharmaceutical compositions based on anticholingerics and additional active ingredients | PDE4B, CHRM3, ADRA2C | CASP2 4108/4885NAAA 2714/4885EPHX1 885/4885 |
| US-20040048886-A1 | Pharmaceutical compositions based on new anticholinergics and NK1 receptor antagonists | CHRM3, CHRNA1, CHRNB1 | CASP2 4585/4885NAAA 1391/4885EPHX1 1853/4885 |
| US-20040097562-A1 | Method for treating tension-type headache | GRIN3A, GRIN2A, GRIK4 | CASP2 3227/4885NAAA 568/4885EPHX1 3627/4885 |
| US-20030212075-A1 | PHARMACEUTICAL COMPOSITIONS BASED ON ANTICHOLINERGICS AND NK1-RECEPTOR ANTAGONISTS | TACR2, CHRM3, TACR1 | CASP2 4578/4885NAAA 1349/4885EPHX1 1916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.